Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company focused on the development of innovative therapies, announces the signing of a binding agreement to acquire 72% of the share capital of Axiodis CRO through its wholly owned French subsidiary, Oxurion France. The transaction amounts to €468,000, valuing the company at €650,000 for 100% of the shares. The closing of the transaction will occur once the two conditions precedent mentioned in this press release have been met. The closing is still expected by the end of June 2025.
Axiodis CRO: a player in clinical biometrics
Founded in 2022 as a carve-out from a company created in 2006 in Toulouse, Axiodis CRO is a Contract Research Organization (CRO) specializing in biometrics applied to clinical trials. A CRO provides services to pharmaceutical or biotech companies.
Axiodis CRO covers the full clinical data management cycle: protocol design, data management, statistical modeling, regulatory reporting, and submission to authorities (EMA/FDA). Its proprietary solution, Exagis, a next-generation eCRF (Electronic Case Report Form) software, combines user-friendliness for investigators with strict compliance to international standards.
Axiodis CRO stands out with its ability to manage complex interventional studies and large, multicenter observational projects (conducted in several institutions or healthcare centers simultaneously, without direct intervention on patients, for observation and analysis purposes) within a rigorous yet agile framework. It supports pharmaceutical companies, medical device manufacturers, and academic institutions with a strong client focus and high regulatory standards.
Technical expertise and integrated operational model
Axiodis CRO operates as a human-scale company, enabling short decision-making processes and close client relationships, mainly with biotech, academic, and institutional sectors. This organizational structure allows fast adaptation to protocol changes or timeline constraints in an increasingly regulated environment.
Axiodis CRO has advanced command of CDISC standards (Clinical Data Interchange Standards Consortium) via a team of experienced data managers and biostatisticians capable of tailoring these standards to real-world projects. Deliverables such as databases, analysis plans, and reports are produced under Standard Operating Procedures (SOPs), with a dual-review process, in full compliance with international standards.
In addition, Axiodis CRO integrates in-house digital skills in R and Python, strengthened by its proprietary SaaS-based Exagis solution, hosted on HDS-certified (Health Data Hosting) infrastructure. This enables secure data centralization, complete traceability, and growing automation of clinical research data flows.
